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Background: The field of cancer genomics has rapidly adopted next-generation sequencing (NGS) in order to
study and characterize malignant tumors with unprecedented resolution. In particular for cancer, one is often trying
to identify somatic mutations – changes specific to a tumor and not within an individual’s germline. However, false
positive and false negative detections often result from lack of sufficient variant evidence, contamination of the
biopsy by stromal tissue, sequencing errors, and the erroneous classification of germline variation as tumor-specific.
Results: We have developed a generalized Bayesian analysis framework for matched tumor/normal samples with
the purpose of identifying tumor-specific alterations such as single nucleotide mutations, small insertions/deletions,
and structural variation. We describe our methodology, and discuss its application to other types of paired-tissue
analysis such as the detection of loss of heterozygosity as well as allelic imbalance. We also demonstrate the high
level of sensitivity and specificity in discovering simulated somatic mutations, for various combinations of a)
genomic coverage and b) emulated heterogeneity.
Conclusion: We present a Java-based implementation of our methods named Seurat, which is made available for
free academic use. We have demonstrated and reported on the discovery of different types of somatic change by
applying Seurat to an experimentally-derived cancer dataset using our methods; and have discussed considerations
and practices regarding the accurate detection of somatic events in cancer genomes. Seurat is available at https://
sites.google.com/site/seuratsomatic.
Keywords: Cancer genomics, Next generation sequencing, Somatic mutation detectionBackground
The rise of next-generation sequencing (NGS) brought
with it a demand for robust tools for variant detection
from sequencing read data, typically after the data has
been aligned against a reference sequence. A variety of
mature analysis tools, workflows and approaches are
already available to the scientific community, and the de-
tection of common types of genomic variation in haploid
and diploid genomes is a rapidly maturing area of devel-
opment [1-3].* Correspondence: dcraig@tgen.org
1Translational Genomics Research Institute, Neurogenomics Division, Phoenix,
AZ 85004, USA
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Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumMore recently, NGS has been employed in order to pro-
vide new insight into the genetic mechanisms of cancer, as
the technology enables the exploration of tumor genomes
in previously infeasible levels of detail. Among many exam-
ples, researchers have used it to examine the patterns of
genomic alteration in non-small-cell carcinoma [4] and mel-
anoma cell lines [5], to discover novel and possibly tumori-
genic mutations in the acute myeloid leukemia genome [6],
and have even used findings to inform clinical treatment of
a patient with acute promyelocytic leukemia [7].
Cancer cells have deviated from the normal (germline)
genome of the organism by acquiring and selecting for a
set of mutations which enable them to grow rapidly and
invasively, to resist regulation and/or possibly to
metastasize [8]. These changes can be simple single-baseentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tural change events. The changes can then trigger the can-
cer process by modifying the function of a protein (e.g.
disabling a tumor suppressor gene, or activating an onco-
gene), silencing a gene’s transcription or affecting a gene’s
transcriptional affinity. In order to separate germline vari-
ants from these acquired (somatic) mutations of the ma-
lignant tissue, many studies have elected to sample and
sequence both the tumor tissue and separate tissue with a
normal genomic profile from the same individual. The
tumor-unique variants are then identified; for this process,
researchers have often decided to use established standard
variant detection tools on both sequenced genomes, and
then apply heuristic filtering methods to establish a set of
confident calls out of the two result sets [5,6].
Cancer genomes, however, pose unique challenges to
variant detection from NGS data that define the effect-
iveness of standard methods. Aneuploidy, massive
genomic amplifications and structural variations are
common in cancer [9]; consequently, the assumption of
a diploid genotype (made by most variant calling soft-
ware) is no longer sound. This is further complicated by
the fact that specific variations are often rare or unique
to each cancer, and cannot be compared to a ‘golden
standard’ genomic profile, even within the same cancer
type. Some cancers are heterogeneous, with some som-
atic variants appearing only in small cell subpopulations
of the malignant tissue. Subpopulation variants however
may be critical to tumor viability [10] and are therefore
interesting to researchers. Finally, tumor biopsies often
suffer from degradation and contamination with non-
malignant tissue to varying degrees, depending on the
type of the tumor and the biopsy method [9]. Generally,
it becomes very likely that analysis and downstream re-
search would be hindered by a high false-negative rate
by variant calling algorithms that do not take these
properties of tumor physiology into consideration.
Presently, tools have been developed or extended with
cancer genomics specifically in mind. OncoSNP [11] uti-
lizes a specialized Bayesian framework for detection of gen-
omic aberrations in cancer, but is designed for the analysis
of single nucleotide polymorphism (SNP) microarray data.
SNVMix [12] is one of the first efforts that serves NGS
studies, and attempts to resolve point mutations in aneu-
ploid genomes using a binomial-mixture model that is opti-
mized using expectation-maximization. SNVMix does not
currently support paired normal/tumor analysis, however.
Other approaches include somatic small variant tool Strelka
[13], the new somatic extensions in the variant-detection
tool VarScan [14], and the specialized Bayesian tool
SomaticSniper [15]. All of the methods mentioned focus on
small genomic events, and none provide specific support
for integrated genome/transcriptome analysis, structural
variation detection or detection of allelic imbalance.We present a generalized Bayesian-based approach for
detecting genomic aberrations unique to one sample set
with the goal of extending beyond detection of point
mutations. Our methods are founded on Bayesian statis-
tical theory and extract a probability value for a somatic
event by comparing the likelihood of the available evi-
dence against all possible explanations (models), and
adjusting the likelihoods with a prior-knowledge prob-
ability for each explanation. While we compare the nor-
mal genome against models with certain assumptions
such as diploidy, the assessment of the tumor data is
only in reference to its similarity with normal data. In-
creased evidence in either the normal or tumor profile
will therefore increase sensitivity by either providing
more evidence towards a somatic change, or more evi-
dence for lack of variation in the normal. Since this
model does not assume a particular distribution of vari-
ant evidence in the tumor, it is robust to changes that
appear in low allelic frequencies, as would possibly be
the case with aneuploid genomes or sequenced samples
that were contaminated by stromal cells. Similarly, the
detection of allelic imbalance is performed by comparing
the likelihood of a ‘balanced’ transcription and the
expected evidence presentation on heterozygous loci,
against the possibility of the tumor/normal variant pro-
portions being independent.
Results
We developed a Bayesian-based analysis framework for
identifying genetic mutations specific to one dataset, as is
the case of somatic mutations within tumors for tumor/
normal pairs. The framework (which we call Seurat) con-
siders the joint probability that a variant is existent within
the tumor dataset but not within the normal dataset.
Seurat iterates through each nucleotide in the refer-
ence sequence and examines any evidence from aligned
reads at that locus. The evidence is then split in two
classes: “Variant” and “Normal” (this process is detailed
in the Methods section). The method can also be applied
with evidence from a sliding window over a reference se-
quence, or evidence from discrete annotated regions
such as exons or whole genes. Depending on the somatic
change that we are attempting to detect, a unit of
“Variant” evidence can be defined as an aligned base that
does not match the reference (indicating a base substitu-
tion), a gap in the alignment (indicating an insertion or
deletion), a mate-paired read with an atypical mate
alignment distance (indicating larger structural vari-
ance), or a read that aligns with unexpected orientation
(indicating an inversion). The normal genome is then
tested for normality given prior expectations of variant
evidence occurring due to error. Then, assuming lack
of genomic events on the normal genome, we proceed
to test the tumor for a proportion of variant evidence
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mal genome. Such dissimilarity would then signify a
somatic event.
Implementation
The methodology could conceivably be implemented on
top of a wide variety of sequence “walkers” that iterate
through aligned short sequence fragments. Our imple-
mentation is a module for the Genome Analysis Toolkit
(GATK) framework [3]. The functionality is exposed
through a command line interface that requires as input
a reference sequence file in the FASTA format, a
reference-ordered data (ROD) file containing gene anno-
tations, and two Binary Alignment/Map files (BAMs)
with the data for the normal and tumor genomes. Out-
put is generated in two text files: One is a list of focal
somatic variants presented the commonly-used Variant
Call Format [16]; the other is a separate catalog of larger
detected events.
The implementation design allows for the creation of
Seurat “sub-modules” that can utilize the core methods
presented for the detection of other small, gene-wide or
exon-wide events that may be supported in the future. The
currently available feature detection modules are listed in
Table 1. Seurat is open-source software, and is available
with a free license for academic and non-commercial use at
https://sites.google.com/site/seuratsomatic.
Evaluation of somatic mutation detection accuracy using
simulated data
Point mutations are aberrations that are frequently ob-
served in cancer genomes, and have been long studied
and causally linked with driving carcinogenesis or
tumor progression, typically by causing the activation of
an oncogene [5,17]. The substitution of a single base
within the coding region of a gene may result in an
amino-acid change or premature truncation of a pro-
tein, and mutations in other regions can cause splicing
errors, transcription silencing, or other potentiallyTable 1 Biological features currently supported by the Seurat
Feature Input d
Somatic base substitutions 1. Norm
2. Tumo
Somatic insertions/deletions 1. Norm
2. Tumo
Somatic loss of heterozygosity 1. Norm
2. Tumo
Allelic imbalance 1. RNA
2. DNA
Somatic structural variance 1. Norm
2. Tumoadverse effects that can trigger abnormal cell prolifera-
tion. Aside from base substitutions, small genomic in-
sertions and deletions (less than 100 bp) are also
common and can disable or alter the result of gene tran-
scription. The effect can range from the addition or re-
moval of amino-acids to the translated protein sequence
to the creation of frameshift event, where the interpret-
ation of codons during translation is changed com-
pletely downstream of the variation.
Seurat detects point mutations by using the counts of
aligned bases that support a variant genotype (e.g. A
non-reference nucleotide or insertion/deletion evidence),
versus the total number of aligned bases. Base substitu-
tions are generally the easiest genomic alterations to de-
tect in alignment data. However, systematic errors are
still often introduced by the alignment process, particu-
larly in homologous regions. Two very useful metrics
that are generally provided by contemporary aligner soft-
ware are the mapping quality and base quality scores.
Mapping quality refers to the confidence that the aligner
software package assigns to its own alignment call, while
base quality scores refer to the sequencing instrument’s
confidence in assigning a genotype to each sequenced
nucleotide. Seurat by default filters data with a mapping
or base quality score that is lower than 10 in the Phred
scale (corresponding to <90% confidence of a correct
call). Another common issue is strand bias, where the
only evidence supporting the variant are reads aligning
in just one direction. As this usually indicates a mapping
artifact, we have added an optional filter which requires
each reported candidate variant to be supported by at
least one read in each direction in order to reduce our
false positive frequency. We also support filtering based
on per-Base Alignment Quality, which is a post-
alignment calculated metric for the probability of a base
mismatch being the result of a misalignment [18].
Typically, failure to detect genetic variants in NGS
data is a result of the inability of the alignment software
to map the sequenced variant reads to the genomic region,software, and their respective input files
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Figure 1 Performance of Seurat’s somatic point mutation
detection with varying genomic coverage. Legend: The sensitivity
(A) and false discovery rate (B) for Seurat’s somatic point mutation
detection method, evaluated on simulated cancer genome data
with no simulated normal tissue contamination. Each series
represents the coverage used for the ‘normal’ genome data set, and
the x-axis represents the ‘tumor’ genome average coverage.
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[1]. This is further complicated in cancer genomes, where
the somatic mutations may be present in only a subset of
the biopsied genetic material [9]. Furthermore, we must
attempt to identify variants that are only in one of the two
genomes, thus a somatic mutation satisfies that (1) it is
not the germline dataset and (2) it is present in the tumor
set. Finally, we do not get to presume diploidy or lack of
normal-tissue contamination in cancer, so variant evi-
dence does not necessarily appear in the often-expected
frequencies of 0%, 50% or 100%.
False-positive somatic mutation calls from paired ge-
nomes are also a non-trivial concern and may derive
from multiple sources. First, instrument and alignment
errors can occasionally present themselves as consistent
and sufficient evidence for variance. Second, it is pos-
sible that a germline variant (i.e. a SNP) can fail to be
detected in the normal genome, and at the same time be
successfully detected in the tumor genome by the ana-
lysis software. This variant will then be misrepresented
as a tumor-specific mutation [9].
Both false-positives and false negatives from the above
example sources of error can theoretically be addressed
through sufficiently high genomic coverage, coupled
with methods that can robustly leverage the additional
data. We have developed a somatic change detection
framework that addresses these considerations. Coverage
at any given place in the genome is variable however,
and low coverage regions may still lend to false-positives
when coverage is not high enough to identify germline
variants.
To evaluate Seurat’s somatic mutation sensitivity and
specificity under a range of realistic conditions, we cre-
ated a simulated cancer dataset using aligned genomic
sequence data from the 1000 Genomes Project [19]. We
appropriated a set of known mismatching polymor-
phisms between two unrelated genomes to be an emula-
tion of known somatic point base substitutions. We also
used two lists of known true negatives, one for each
source of false positive calls described above (reference
genotype in both samples/ variant genotype in both
samples).
Effect of normal and tumor coverage on detection
performance
The simulated data for both normal and tumor were
down-sampled to generate sets with varying average
coverage, in order to explore the effect of sequencing
throughput to accuracy. Seurat was then used to analyze
each combination of down-sampled normal/tumor pairs,
and the output for each combination was compared to
the ground truth sets to measure sensitivity and false
discovery rate (FDR), as we present in Figure 1. We have
found that increases in normal and tumor sequencingoutput both translate to a rise in mutation sensitivity,
and the best improvement gradient comes from the sim-
ultaneous raise in both normal and tumor coverage,
peaking at ~0.98 at the 128× level, while maintaining a
FDR under 0.02. This ability to increase both sensitivity
and specificity by sequencing more of just the normal
genome can be very useful in cases where genetic mater-
ial from the tumor is scarce or hard to acquire.
Effect of heterogeneity on detection performance
From the above simulated normal/tumor dataset, we
derived another series of datasets where the tumor
sequence was now admixed with normal sequence
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sequence remained constant at 128×. Along with Seurat,
we used this range to evaluate three additional popular
and publically-available normal/tumor analysis packages:
Strelka [13], SomaticSniper [15] and Varscan 2 [14]. De-
tails and paremeters for this comparison can be found in
[Additional file 1].
Figure 2 shows our results. We found that Seurat is
able to discover >90% of the simulated mutations for
tumor purity as low as ~45%. Both Seurat and Strelka
are able to call ~50% of variants at 10% purity, while the
sensitivities of SomaticSniper and VarScan are signifi-
cantly lower at the lower purity levels with these specific
datasets and scenarios. It’s important to highlight that
any comparison is subject to biases of the individual
tests and do not imply that a software is ‘better’ or
‘worse’ for a specific situation. However, these compari-
sons do shed light on strengths and weaknesses of
Seurat within the confines of tumor heterogeneity.
Application to experimental cancer sequencing data
We applied Seurat to a cancer sequencing dataset from
a patient diagnosed with a rare, late-stage lymphoma.
Sequencing was performed on an Illumina Genome
Analyzer IIx instrument, sequence alignment was
performed using the CASAVA software package and the
resulting BAM files were processed by our implementa-
tion. Analysis with Seurat was performed using 24 Intel
Xeon Harpertown cores at 2.83 GHz (4 GB of RAM
allocated to each core) and a Lustre distributed file sys-
tem for high-performance input/output. The process
was completed in approximately 5 hours, and Seurat
produced locus and probability output for candidate
somatic base substitutions, indels, loss of heterozygosity
and structural variation events. We summarize our re-
sults and their additional evaluation in Table 2. The high
transition/transversion ratio, low non-synonymous/syn-
onymous ratio and low dbSNP rate indicate Seurat’s high
specificity and low false discovery rate, and variants with
a Phred-scale quality of over 20 predictably perform
even better in these metrics.
Loss of heterozygosity (LOH)
Loss of heterozygosity (LOH) refers to a genomic dele-
tion that removes a functional copy of an allele in a cell.
In the context of cancer, LOH events are usually import-
ant in occasions where the second allele of a gene was
already mutated or inactive; typically this gene would be
a known tumor-suppressor gene that would now be-
come completely disabled. This can be an early event or
a necessary condition for the instigation of cancer, and
LOH of the TP53 and RB tumor-suppressor genes have
been studied for their role in a wide variety of human
cancers [22,23].LOH events can be detected using a similar way as
base substitutions, but the expectation of variant allele
evidence is rather placed on the normal-tissue genome
data, while the tumor genome is expected to be ‘variant-
free’. We have observed that the proportions of refer-
ence to variant evidence can vary wildly between
datasets, signifying that the relative alignment “affinity”
of each of the alleles is highly sensitive to subtle changes
in protocol (i.e. sample preparation, sequencing environ-
ment, revisions of the alignment software). Contrasting
our somatic mutation method, we decided to not use
the evidence from the normal genome to “update” the
idea of the expected genotype – systematic shifts were
introducing a very high rate of false positives.
Structural variation
It is also possible to observe major structural genomic
changes via alignment data. For mate-paired sequencing,
the aligner software will attempt to match the two se-
quenced fragments within the insert size distance and
orientation that is expected by the sample sequencing
biochemistry and protocol. If that is not possible, the
fragments will be aligned independently and the
resulting alignment file will include the information
about the unexpected event.
Under our method, each ‘abnormal’ fragment can
count as a piece of variant evidence. Abnormal frag-
ments that belong in the same variant ‘subclass’, (such as
reads whose mates all align in the same trans- region)
can for example be evidence of a genomic translocation.
A significant number of abnormal reads with properly
oriented mates in the same chromosome can be the re-
sult of a large deletion, while a cluster of abnormally-
oriented reads can be because of an inversion event.
Using our somatic mutation formula, a somatic struc-
tural event is once again indicated by such evidence
appearing primarily and confidently in the tumor.
Discussion
We have presented a paired genome analysis method
and accompanying software package for cancer genomes
and transcriptomes. The Bayesian approach and the use
of beta-binomial probability distributions were shown to
be useful in modeling the uniqueness of genotype dis-
covery in cancer. Admixed genomes, as well as unpre-
dictable ploidy in tumor DNA, can be accounted for;
and higher coverage increases the method’s ability to
discover somatic variants with very low allelic frequency.
Seurat uses the data in the normal genome to ‘update’
the beta-distribution used for the detection of somatic
mutations, meaning that an increase in sequencing
coverage in either normal or tumor genomes will benefit
accuracy. Figure 3 demonstrates how additional sequen-
cing of the normal genome can help with both rejection
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Figure 2 Performance of somatic point mutation detection with varying tumor purity. Legend: The sensitivity (A) and false discovery rate
(B) for Seurat, VarScan 2, Strelka and Somaticsniper, given tumor DNA data of varying simulated tumor purity. Seurat reaches 90% sensitivity at
~45% tumor purity in sequence data with average genomic coverage of 128 × .
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low allelic frequency. Though this can be a useful attri-
bute when only the normal tissue is available for
additional sequencing runs, sensitivity will still remain
low if the tumor alignments do not yield more than 2–3reads containing the somatic variant (if, by chance, the
mutated allele is not sampled enough). When deciding
on the amount of sequence to produce, it is therefore
useful to consider (and if possible, to estimate) the purity
of the tumor tissue or the possibility of tumor
Table 2 Summary of analysis results from the application
of Seurat on an experimentally derived cancer dataset
Metrics (example tumor/normal dataset)
Average genomic coverage on normal tissue genome 55×
Average genomic coverage on tumor tissue genome 40×
Somatic base substitutions 29526
Somatic base substitutions (Quality > 20) 17044
Transition/Transversion ratio for somatic base substitutions 1.433
Transition/Transversion ratio for somatic base substitutions
(Quality > 20)
1.922
dbSNP build 135 rate 0.146
dbSNP build 135 rate (Quality > 20) 0.088
Somatic insertions 1430
Somatic deletions 4067
Somatic structural variance sites 272
Somatic loss of heterozygosity sites 1523
Non-synonymous/Synonymous mutation ratio 0.00435
Detailed Legend: Summary of somatic mutation analysis details from the
application of Seurat on a normal/tumor genome pair of a patient with a rare
lymphoma. The dbSNP rate refers to the proportion of candidate somatic
variants that are included in the public genomic variation database dbSNP
[20]. This number is an indicator of known germline variants that were falsely
identified as tumor-specific. The calculation of the transition/transversion and
the non-synonymous/synonymous variant ratios was performed using snpEff
[21].
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50%, there will be an expected ~6% decrease in sensitiv-
ity if the coverage averages 128×; the drop will be higher
for a lower average coverage.
We have demonstrated how our methods are able to
accurately detect a variety of somatic events that are
linked to cancer such as point mutations (base substitu-
tions, insertions and deletions), LOH events between ge-
nomes and certain types of structural variation such as
translocations and large deletions.
The Bayesian framework used in Seurat is not limited
to analysis of DNA mutations. It’s also possible to use
the tumor’s sequenced transcriptome to detect allelic
imbalance events in a set of known and annotated tran-
scripts by evaluating the probability of a significant shift
in the distribution of heterozygous bases. If the aligned
transcriptome of the normal tissue is provided, one will
be able to detect allelic imbalance events that only occur
in the tumor. Otherwise, the tumor DNA will be used
to establish normal distribution of heterozygous evi-
dence instead, and the results may include unbalanced
alleles that also exist in non-cancerous cells. These ap-
proaches represent currently available experimental ana-
lysis within Seurat, and are mentioned to demonstrate
the generalizable nature of the Bayesian-based analysis
scheme. The immediate challenge with determining suchpriors is that lack of experimental systems with known
truth allele specific shifts. Future efforts will be needed
to optimize appropriate priors for detection of allele spe-
cific expression that specifically capture the unique char-
acteristics of comparing RNA and DNA derived data
aligned separately through independent pipelines.
Conclusions
In summary, paired-genome sequencing in cancer can
present us with a highly accurate view of how the cancer
genome has evolved from a normal cell’s DNA. It is then
beneficial to cancer genomic research that we continue
the exploration of paired-genome analysis algorithms, in
order to extract a clearer picture of a tumor’s profile and
even its evolutionary narrative.
Methods
Evidence classes
For the purposes of our methods, evidence is grouped
by the genotype that they indicate. Non-variant align-
ments are ones that do not point to a change from the
reference genome while variant alignments are split into
subclasses. Each subclass stands for a specific genotype
change that is being proposed, and each subclass is then
sequentially tested. Classifying all evidence in a binary
fashion (“supporting variant” versus “supporting non-
variant”) allows us to regard each piece of evidence as a
Bernoulli trial, where a success is evidence for a specific
change, and failures are everything else.
Simulated data
In order to test accuracy of our methods, we emulated the
existence of somatic point mutations by comparing two
unrelated human genomes. We used publically-available
exome sequence data from the 1000 Genomes project for
this purpose (available from http://www.1000genomes.
org). We chose the samples NA19240 and NA12878 as
“normal” and “tumor”, respectively. The sequence data
was generated using Illumina instruments, and aligned
using the MOSAIK software package. For our variant
truth set, we used validated genotype calls that are avail-
able for these same individuals from the Hapmap project
(International HapMap Consortium 2003). From these
genotype lists we extracted a list of true positives (sites
where the normal genotype matches the reference, but the
tumor genotype does not), and two lists of true negatives
(sites where both samples match the reference, and sites
where both samples do not).
To simulate normal-tissue contamination and gener-
ally low allelic frequencies in the presentation of somatic
variants, we developed an in-house tool based on
the Picard SAM manipulation library (http://picard.
sourceforge.net) that randomly selects aligned reads
from the two alignment data files at a user-specified
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Figure 3 The effect of increased sequencing of the normal genome on Seurat’s somatic mutation detection. Legend: Demonstration of
the effect of increased sequencing of the normal genome in a matched normal/tumor analysis using Seurat. We present three common
scenarios: A) a locus with a true somatic variant, but presented with low frequency of the variant allele, because of mapping difficulty, low purity
of the tumor biopsy or because of the variant being present only in a minor sub-clonal population. B) a locus with a potential false-positive call,
because of erroneously-aligned variant evidence. C) a locus with a variant genotype in the normal genome, but with a coincidental lack of
evidence causing it to appear as a tumor-only variant. In all three scenarios, the increase in sequencing data available for the normal genome
updates the expectation of variant evidence (by altering the shape of the conjugate beta distribution) and consequently amplifies Seurat’s
capability to correctly reject the last two cases and accept the first case.
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to create created new BAM files for a range of simulated
tumor purity ratios. The new datasets can then be paired
with the individual that was tagged as ‘normal’, and given
as input to the software.
Somatic mutation detection
We define the probability of a somatic mutation event
(P(somaticSNV)) as the joint probability of a non-
variant genotype being detected in the normal genome
(P(refnormal)) and a variant genotype being detected in
the tumor genome P(¬reftumor).PðsomaticSNVjDnormal;Dtumor ¼ PðrefnormaljDnormalÞTable 3 Description of priors used in Seurat
Symbol Description Default values
πι Genotype prior probabilities πvar = 0.0005
πhet = 0.001
πref = 1 – (πhet + πvar) =
0.9985
πsomatic = 0.0001
πLOH = 0.0001
αι, βι Alpha and beta hyperparameters
for the beta distributions of
variant allele proportions
αref = 1, βref = 700
αvar = 700, βvar = 1
αnonhom = 1, βnonhom = 1
αsomatic = 1, βsomatic = 1
αAI = 1, βAI = 1
Detailed Legend: A list of the priors and hyperparameters used by Seurat, and
their assigned values. The priors used for the genotype in the normal genome
are the SNP frequencies for human diploid chromosomes, as calculated by Li
et al. [24]. πsomatic and πLOH are high-end estimates of the frequency of
somatic events, given that that the mutation profile of each individual cancer
can vary wildly even within subtypes. At 0.0001, they expect 300,000 events
through the human genome.In the case of detecting somatic point mutations, each
nucleotide of the reference sequence is evaluated inde-
pendently given that it is sufficiently covered by aligned
sequence on both normal and tumor genomes (by de-
fault , we take sufficient coverage to be a minimum of 5
aligned bases that pass base and mapping quality filter-
ing). Dnormal and Dtumor are the sets of mapped bases
(base pileups) for the normal and tumor genome, re-
spectively. Interpreting the base pileups as Bernoulli tri-
als, a success signifies an alignment that differs from the
reference sequence (base mismatch, or a read alignment
with an insertion/deletion edit at the tested site), and a
failure is a mapped base that matches it.
Given that the examined locus is homozygous and
matches the reference, the success probability of the Ber-
noulli trials is expected to be near zero and the genotyp-
ing error rate of the sequencing instrument. This
success proportion can, however, be highly variable - be-
cause of possible systematic sequencing and aligner soft-
ware biases, as well as variability in the mappability of
the reference sequence.
We use a beta-binomial distribution to model the
probability of the evidence, given a genotype that
matches the reference. The beta-binomial distribution
uses a beta distribution as a probability density function
for the proportion of success (variant); this allows us to
model the uncertainty of its true value.
 Pð reftumorjrefnormal;Dnormal;Dtumor¬P Dnormal refnormalj Þ ¼ beta binomialpmf
Nnormal;Knormal; αref ; βref
 
The hyperparameters α and β of the beta distribu-
tion in this case are set so as to skew the curve to
zero. These parameters can be adjusted at the com-
mand line using any additional knowledge of the error
profile.
We then apply Bayes’ theorem to extract a prob-
ability for homozygosity. Since we can assume that
the normal genome is diploid, the marginal probabil-
ity of the evidence (P(Dnormal)) can be taken to be
the sum of the likelihoods of the evidence given
the three possible genotype classes (homozygous
matching the reference, homozygous variant to the
reference, and heterozygous). The selected default
values for the prior probabilities for each genotype
(πi), as well as the hyperparameters αι and βι are
listed in Table 3.
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The second half of the method is a similar calculation
with two major differences. Firstly, we are now looking at
the cancer genome so we will no longer assume diploidy
or an expected allele frequency. Therefore we use the un-
informative beta distribution with parameters [α = 1, β = 1]
for variants, and the genotype classes are reduced to just
“reference-homozygous” and “somatic variant”.
Secondly, we can use the evidence observations from
the normal genome to ‘update’ our beta distribution
used for the reference homozygosity calculation. This is
a simple case of adding the count of successes and fail-
ures to the α and β parameters respectively.
PðDtumor refnormal; ref tumorj Þ ¼ beta binomialpmf
Ntumor;Ktumor; αrefþKnormal; βrefþNnormalKnormal
 
This property of beta distributions helps to overcome
the imprecision of priors and the variability of the error
rate; in the case of very high-coverage data such a
targeted sequencing or whole-exome projects, the nor-
mal evidence can virtually overcome the prior beta dis-
tribution and allow for sensitive and specific detection of
very low-frequency variants. Finally, Bayes’ Theorem
yields:
Pð:reftumor refnormal;Dnormal;Dtumorj Þ
¼ πsomatic  PðDtumor :reftumor; refnormalj Þ
∑Gi πi  P Dtumor i; refnormalj Þð
Detection of somatic loss of heterozygosity
Testing for somatic loss heterozygosity in our method-
ology would come from the joint probability of a non-
homozygous genotype in the normal genome and a
homozygous genotype in the tumor genome (either
reference-homozygous or variant-homozygous). The pre-
sentation of a non-homozygous genotype in the tumor
genotype is once again updated using the evidence from
the normal:
PðsomaticLOH Dnormal;Dtumorj Þ
¼ Pðhetnormal Dnormalj Þ
P :hettumor hetnormal;Dtumorj Þð
PðDtumorj reftumor; refnormalÞ
¼ beta binomialpmfðNtumor;Ktumor;αsomatic; βsomatic
¬Pð:hettumor hetnormal;Dnormal;Dtumorj Þ
¼ πLOH PðDtumor :hettumor; hetnormalj Þ
∑Gi πi  P Dtumor i; hetnormalj Þð
The presentation of a non-homozygous genotype in
the tumor genotype is once again updated using the evi-
dence from the normal:
PðDtumor hetnormal; hettumorj Þ
¼ beta binomialpmfðNtumor;Ktumor; αref
þKnormal;NnormalKnormalÞ
Allelic imbalance detection
We use a similar method to somatic point mutation dis-
covery in order to compute the probability of allelic ex-
pression imbalance of a transcript (AI). Starting with
paired normal and tumor RNA alignment data, the
mapped bases for each nucleotide in the reference se-
quence are once again translated to Bernoulli successes
and failures. A Bayes factor is then used to compare the
likelihoods of the tumor transcript data a) if the variant
allele proportion is equal to the proportion of the nor-
mal sample at the same locus (no somatic AI) and b) if
the proportions are independent.
PðDtumor M2;G;Dnormalj Þ
¼ beta binomialpmf K ;N ; αG; βG
 
; G→ Ref ;Varf g
beta binomialpmf K ;N ; αAI ; βAIð Þ; G→ Hetf g

PðDtumor M1;G;Dnormalj Þ
¼
(
beta binomialpmf K ;N ; αG; βG
 
;
G→ Ref ;Varf g
beta binomialpmf K ;N ;Knormal;Nnormal−Knormalð Þ;
G→ Hetf g
)
K ¼ ∑
G
i πi PðDtumor M1; i;Dnormalj Þ
∑Gi πi P Dtumor M2; i;Dnormalj Þð
The implementation requires that gene annotations
are provided, which are used to limit the process only
to loci where reads have aligned within a known tran-
script. For each sufficiently covered nucleotide in a
transcript region the likelihood calculations are
performed, and the prior odds are multiplied with the
Bayes factor K to give us the updated (posterior)
odds.
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